Total n=63
Typical ColdU n=39
Atypical ColdU n=24
p-value
Gender: Female Male 50 (79%) 13 (21%) 31 (80%) 8 (20%) 19 (79%) 5 (21%)
0.976
Age (years) (min-max) 42 (18-69) 42 (18-69) 42 (19-66) 0.804
CSU 8 (13%) 5 (13%) 3 (13%) 0.970
Comorbid CIndU: 18 (29%) 9 (23%) 9 (38%) 0.218
- symptomatic dermographism, 12 (19%) 6 (15%) 6 (25%) 0.345
- cholinergic urticaria 7 (11%) 5 (13%) 2 (8%) 0.582
- heat urticaria 1 (2%) 0 1 (4%) 0.199
- delayed pressure urticaria 4 (6%) 2 (5%) 2 (8%) 0.612
- vibratory urticaria 1 (2%) 0 1 (4%) 0.199
- solar urticaria 2 (3%) 0 2 (8%) 0.067
- contact urticaria 1 (2%) 1 (3%) 0 0.429
- aquagenic urticaria 0 0 0 -
- 2 types or more 13 (21%) 8 (21%) 5 (21%) 0.976
Angioedema 33 (52%) 22 (56%0 11 (46%) 0.414
Hypotensive episodes 4 (6%) 1 (3%) 3 (13%) 0.116
Allergic rhinitis 20 (32%) 10 (26%) 10 (42%) 0.185
Asthma 14 (22%) 8 (21%) 6 (25%) 0.677
Atopic dermatitis 2 (3%) 2 (5%) 0 0.423
Autoimmune disorders 15 (24%) 10 (26%) 5 (21%) 0.663
Oncology 2 (3%) 2 (5%) 0 0.260
Family history of ColdU 6 (10%) 3 (8%) 3 (13%) 0.528
H1-Antihistamines licensed doses 50 (79%) 31 (79%) 19 (79%) 0.976
H1-Antihistamines escalated doses 9 (14%) 6 (15%) 3 (13%) 0.751
Omalizumab 2 (3%) 2 (5%) 0 0.260
Duration of ColdU (months) 60 (11-360) 24 (11-71) 212 (60-360) <0.001
UCT 11 (6-16) 10 (6-13) 13 (9-16) 0.028
DLQI 4 (0-10) 6 (2-10) 0 (0-4) 0.006